Qiming Weekly | Top 10 News from Qiming Venture Partners' Portfolio Companies Vol.21, 2026.6.23
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: In 2026, the Qiming Weekly gets a refresh — updated regularly each week with a curated selection of ten major developments from Qiming Venture Partners portfolio companies, covering funding milestones and breakthrough progress.
Every step entrepreneurs take in the tide of technology and innovation deserves to be recorded. Qiming Venture Partners will continue accelerating and empowering founders, and we invite you to follow along as we track these milestone moments together.
Major Partnerships
01/
Insilico Medicine Signs $2.5 Billion AI Drug Discovery Partnership with SK Biopharmaceuticals
Qiming Venture Partners portfolio company Insilico Medicine (03696.HK), a generative AI-driven clinical-stage biotech, and SK Biopharmaceuticals, a Korea-headquartered company pioneering innovative drug research, jointly announced an AI-powered drug discovery collaboration on the eve of BIO 2026. The partnership will focus on neuroimmune diseases, leveraging AI technology to identify novel drug candidates.
Neuroimmune diseases — encompassing neuroinflammatory conditions, neurodegenerative disorders, and rare neurological diseases — represent one of the most challenging therapeutic areas in modern medicine, with significant unmet clinical needs and historically low clinical success rates for drug development. Under the agreement, Insilico Medicine will apply its proprietary Pharma.AI platform, which spans target validation, molecular generation, and molecular optimization, alongside its preclinical drug discovery expertise, to identify, design, and optimize novel candidates for neuroimmune indications. SK Biopharmaceuticals will contribute its deep R&D and clinical capabilities in neuroimmune diseases, leading late-stage development and commercialization. The partners aim to accelerate drug discovery and bring next-generation therapies to patients worldwide faster.
02/
WeRide and Uber Launch Robotaxi Service in Zurich, Second European City
Qiming Venture Partners portfolio company WeRide (NASDAQ: WRD, 0800.HK), a global leader in autonomous driving technology, and international mobility giant Uber (NYSE: UBER) announced plans to launch commercial Robotaxi service in Zurich, Switzerland. This marks the second European city where the two companies have partnered on Robotaxi deployment, following Madrid, Spain, as WeRide's European commercial footprint continues to expand.
With support from the Swiss Federal Roads Office (FEDRO), the Zurich Robotaxi service is expected to launch within the year. Upon regulatory approval, local users will be able to hail a WeRide Robotaxi through the Uber app. WeRide has already established a leading autonomous driving commercial presence in Switzerland. In January 2025, WeRide Robobus began operations at Zurich Airport, becoming Europe's first airport autonomous driving deployment and achieving front-seat-unmanned commercial operation. In November 2025, WeRide Robotaxi received Switzerland's first fully driverless license and began trial operations with the Swiss Transit Lab (STL) and Swiss Federal Railways (SBB), further cementing its first-mover advantage in autonomous driving commercialization.
03/
Biren Technology Enables Efficient Support for Zhipu AI's Flagship GLM-5.2 Model
Qiming Venture Partners portfolio company Zhipu AI (02513.HK) recently officially open-sourced its next-generation flagship model GLM-5.2. Biren Technology's Bili™ 166 series, based on the vLLM inference framework, completed "Day 0" adaptation and optimization for the model, becoming the first to offer developers and users rapid deployment solutions and efficient, stable long-horizon task experiences.
Leveraging its self-developed full-stack multi-agent orchestration platform SUPACODE and mature BIRENSUPA™ software stack, Biren Technology rapidly achieved GLM-5.2 model adaptation and optimization. Through SUPACODE's automated analysis, intelligent operator tuning, and critical path optimization, Biren Technology quickly completed model functional adaptation and precision alignment. Building on the vLLM inference framework, it fully unleashed the compute and memory advantages of Bili™ 166. Biren Technology independently designed multi-dimensional optimization strategies including expert parallel scheduling, sparse attention operator optimization, and computation graph reconstruction, achieving significant large language model inference performance gains without precision loss — providing a reusable optimization paradigm for efficient MoE-class large model deployment on the Bili™ series.
04/
Shengshu Technology and Guanglun Intelligent Form Strategic Partnership
Qiming Venture Partners portfolio company Shengshu Technology and Guanglun Intelligent recently announced a strategic partnership. The two sides will deeply collaborate on establishing data standards for general world models, building high-quality world model evaluation systems, and accelerating world model scenario deployment — driving general world models toward "physical trustworthiness, task usability, and real-world verifiability."
Shengshu Technology draws on its deep technical expertise in general world models, with the World Action Model MotuBrain at its core, building an embodied intelligence general brain that unifies "world prediction" and "action driving" in a single model. Guanglun Intelligent focuses on human data, simulation evaluation, and deployment feedback to build data and evaluation infrastructure for physical AI, and drives continuous iteration between real-world experience and digital-world capabilities through its self-developed full-stack simulation platform integrating "solving-measuring-generating." The partners will jointly advance three priority areas: high-quality world model data systems, reproducible world model evaluation systems, and real-world scenario validation with continuous iteration mechanisms.
Product Launches
01/
Zhipu AI Releases and Open-Sources GLM-5.2
Qiming Venture Partners portfolio company Zhipu AI (02513.HK) recently released and open-sourced GLM-5.2. On Code Arena, a front-end development evaluation system with one million users participating in blind tests globally, GLM-5.2 achieved first-place performance among all available models.
On the path to AGI, Zhipu AI is targeting fully autonomous agent systems. Building on long-horizon tasks, AI-driven, collaboratively operating, 24/7 agent collectives will become a new form of productive force. The evolution from "intelligent assistant" to "digital employee" means constructing a society of thousands of agents with different professional "personalities" and "skills" — agents that autonomously debate, collaborate, review code, and allocate resources, achieving "self-driving" level digital productivity. Many core technologies still require breakthroughs: Memory, Continual Learning, and Self-Judge.
02/
Mech-Mind Launches Flagship Embodied Intelligence "Eye-Brain-Hand" Product Mech-Eye ULTRA M
Qiming Venture Partners portfolio company Mech-Mind officially launched its next-generation robotic 3D vision system — the Mech-Eye ULTRA M high-resolution, high-speed structured-light flagship industrial 3D camera. Based on self-developed core components and advanced AI imaging algorithms, Mech-Eye ULTRA M features ultra-high resolution and imaging speeds as fast as 0.08 seconds, giving robots the ability to perceive minute details and react at extreme speed. It effectively solves recognition and grasping challenges for thin-walled workpieces (<1mm) and transparent objects, easily matching the extreme cycle times of high-speed production lines for express parcel handling, retail picking, and more — accelerating the deployment of intelligent robots in complex scenarios.
As Mech-Mind's flagship embodied intelligence "eye-brain-hand" product, the Mech-Eye ULTRA M launch further strengthens the product matrix, providing integrators and partners with more powerful product support to help them open up new scenarios and applications. Currently, general-purpose robot "eye + brain" systems have been deployed globally in over 24,000 units. With strong technology iteration and product upgrade capabilities, we will further accelerate the large-scale deployment of embodied intelligence technology across thousands of industries.
R&D Progress
01/ Zai Lab Announces Zocilurtatug Pelitecan (Zoci) Receives EMA Orphan Drug Designation
Qiming Venture Partners portfolio company Zai Lab (NASDAQ: ZLAB, 09688.HK) announced that the European Medicines Agency has granted orphan drug designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), a potentially first-in-class antibody-drug conjugate (ADC) targeting Delta-like ligand 3 (DLL3), for the treatment of pulmonary neuroendocrine carcinoma.
The designation is based on a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP). The committee recognized the severity of neuroendocrine carcinoma and the urgent need for new treatment options. Small cell lung cancer is the most common pulmonary neuroendocrine carcinoma, with approximately 2.5 million new lung cancer cases diagnosed globally each year, of which small cell lung cancer accounts for about 15% (an estimated 375,000 annual new cases) — one of the most rapidly progressing and lethal solid tumors. In granting the designation, COMP noted that preliminary clinical data in relapsed or refractory extensive-stage small cell lung cancer patients suggest zoci may demonstrate superior efficacy compared to existing approved therapies, including durable responses, which the committee deemed clinically relevant.
02/
Pushi Lihua Secures Position in Tuberculosis Diagnostic Procurement Channel with World's Only NPOC Solution
Qiming Venture Partners portfolio company Pushi Lihua recently received its first definitive signal of entry into The Global Fund system, with initial purchase orders exceeding $13 million secured. Behind these 13-country projects lies a $50 million commitment from the Children's Investment Fund Foundation (CIFF) to The Global Fund — the foundation's first investment in tuberculosis diagnostics, specifically earmarked to accelerate the introduction and scale-up of the entirely new NPOC solution. As the currently sole provider in this category, Pushi Lihua secured initial confirmed purchase orders exceeding $13 million.
Pushi Lihua entered The Global Fund's Early Adopter Initiative, a mechanism that allows innovative technologies to complete real-world validation, policy groundwork, and supply chain testing before large-scale procurement. The program covers 13 countries, led by The Global Fund with support from the Children's Investment Fund Foundation (CIFF) and frontline implementation by the Aurum Institute.
Notably, the introduction in these countries departs from the typical small-scale pilots common for new technologies. Previously, new diagnostic technologies usually started with 5 to 10 sites per country; this time, countries are deploying directly at 40, 100, or even 200 sites based on their circumstances. This "scale from day one" posture itself represents a direct signal of procurement system demand intensity for this solution.
The 13 countries are Bangladesh, Benin, Cameroon, Ethiopia, Indonesia, Kenya, Nigeria, Peru, Philippines, South Africa, Uganda, Vietnam, and Zambia. By entering through this early window, Pushi Lihua gains first-mover position in the procurement system and the opportunity to help define standards, pricing, and processes before they become fixed.
03/
Gan & Lee Pharmaceuticals' Bofanglutide Ib/IIa Phase Glycemic Control Clinical Results Published Again in Cell Reports Medicine
Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that its self-developed Class 1 new drug — Bofanglutide (GZR18) injection — following international recognition for its Ib/IIa phase weight reduction study, saw its Ib/IIa phase glycemic control clinical results in Chinese type 2 diabetes patients published on June 19 in the internationally authoritative journal Cell Reports Medicine. The journal's latest impact factor is 14.0, ranking in Q1 of the Chinese Academy of Sciences Medical Sciences category. The study results demonstrate that Bofanglutide injection can significantly reduce blood glucose levels in type 2 diabetes patients, improve multiple cardiovascular and metabolic risk factors, with overall good safety and tolerability.
In April this year, Gan & Lee Pharmaceuticals' insulin aspart and insulin lispro raw materials passed GMP certification by Brazil's Health Regulatory Agency (ANVISA). This means the company's insulin glargine, insulin lispro, and insulin aspart products have achieved dual compliance certification for both raw materials and formulations in Brazil, with manufacturing quality systems fully meeting local pharmaceutical regulatory standards — laying a solid foundation for the company's own insulin brands to formally enter the Brazilian market and deepen its presence in the Latin American pharmaceutical market.
Technical Capabilities
Axera Makes Appearance at 2026 Chongqing Auto Show
Recently, Qiming Venture Partners portfolio company Axera (00600.HK) officially appeared at the 2026 Chongqing Auto Show · Future Automotive AI Technology Exhibition.
As an AI computing chip platform company, Axera showcased its latest technology, products, and commercialization progress in automotive chips and computing platforms, including its self-developed series of automotive-grade intelligent driving chips, chip reference development platforms, and partner hardware and software solutions. It also presented assisted driving function road test videos based on its chips, developed by domestic and international algorithm partners, visually demonstrating technical capabilities from underlying computing power to intelligent driving applications.
On commercialization and partnership ecosystem: In 2025, the company partnered with over 15 OEM brands, including more than 5 international brands, with large-scale, global cooperation entering the fast lane. Its ecosystem partnership map currently encompasses 50+ partners — forming a complete matrix spanning supply chain, foundational software, application algorithms, and integration Tier 1s.
PAST REVIEWS
Qiming Perspectives | Duane Kuang, Qiming Venture Partners: Embrace the Cycle, Ride Through the Cycle — AI Will Be an Ultra-Long Technology Cycle Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.17, 2026.5.26 Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including ChinaVenture 2025 Top 4 Best VC Firms
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Haobio, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.